RXDX 107Alternative Names: CEP-40125; RXDX-107
Latest Information Update: 05 Oct 2016
At a glance
- Originator Cephalon
- Developer Ignyta
- Class Antineoplastics; Benzimidazoles; Butyric acids; Nitrogen mustard compounds; Nitrosourea compounds; Small molecules
- Mechanism of Action Apoptosis stimulants; DNA cross linking agents; DNA synthesis inhibitors; Mitosis modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours